Unity Biotechnology
Unity Biotechnology, based in Brisbane, CA, is pioneering innovative therapeutics that target the biology of aging, with a particular emphasis on treating retinal diseases. Their lead senolytic candidate, UBX1325, offers a novel mechanism of action that aims to deliver longer-lasting improvements in vision for patients suffering from diabetic macular edema.
At the forefront of cellular senescence research, Unity Biotechnology is dedicated to restoring diseased tissues to a healthier state through a new class of treatments. Recent positive clinical data from their Phase 2 BEHOLD study highlights the significant potential of UBX1325 in improving vision outcomes, with further evaluation underway in the Phase 2b ASPIRE study.
Generated from the website
Also at this address
You might also like
Partial Data by Foursquare.